NTRK1 and central nervous system cancer: In another study, an N-linked glycosylation small molecule inhibitor (NGI-1) was able to reduce glycosylation and activation of receptor tyrosine kinases to inhibit tumor cell growth and increase epidermal growth factor receptor family activation, improving glioma cell sensitivity to radiotherapy and chemotherapeutic agent cytotoxicity12.